Five-year Study Findings Published in the Journal of the Neurological Sciences
JERUSALEM, Israel–Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE® (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies (DMTs).
Though all DMT treatment arms resulted in a reduction in brain volume loss compared to the control group of non-treated patients, COPAXONE® had a significantly better effect than both low and high dose interferons, in reducing loss of brain volume. A paper published by Dr. Omar Khan, detailing the study findings, “Effect of disease-modifying therapies on brain volume in relapsing–remitting multiple sclerosis: Results of a five-year brain MRI study,” was recently published in the Journal of the Neurological Sciences.
“These data represent the importance of ongoing research in a practical clinical setting to better understand multiple sclerosis and the impact of therapy on the course of the disease ,” said Jon Congleton, Senior Vice President and General Manager, Teva Neuroscience. “Not only does this study highlight the benefit of COPAXONE® in reducing brain volume loss, it underscores the value of early treatment in influencing long-term outcomes.”
Brain volume loss in multiple sclerosis patients exceeds the rate of healthy control groups. Brain volume loss, sometimes referred to as atrophy, may be correlated with cognitive and physical deficits. Modern magnetic resonance (MR) techniques can reliably measure loss of brain volume over time.
ABOUT THE STUDY
In the study, the COPAXONE® treatment arm resulted in a -2.27 percent change in brain volume (PCVB) as compared to baseline versus -2.62 percent for Avonex® (low-dose interferon), -3.21 percent for Betaseron®/Rebif® (high-dose interferon).
===========================================================
Remain CURRENT with Multiple Sclerosis news and information
REGISTER HERE MS Views and News
.
.Providing You with ‘MS Views and News’, is what we do
.
On the 4th Wednesday of each month
Listen-to StuMSRadio Online at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions
.
“MS Views and News” is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service
.. All contributions are tax deductible to the fullest extent allowed by law
.===========================================================
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews